COYA
Coya Therapeutics Inc

1,123
Mkt Cap
$89.56M
Volume
385,311.00
52W High
$8.29
52W Low
$3.94
PE Ratio
-3.88
COYA Fundamentals
Price
$4.28
Prev Close
$4.03
Open
$4.11
50D MA
$5.67
Beta
0.91
Avg. Volume
201,096.59
EPS (Annual)
-$0.9765
P/B
2.63
Rev/Employee
$444,257.63
Loading...
Loading...
News
all
press releases
Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients
Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with...
Business Wire·12d ago
News Placeholder
More News
News Placeholder
D. Boral Capital Reiterates "Buy" Rating for Coya Therapeutics (NASDAQ:COYA)
D. Boral Capital reissued a "buy" rating and issued a $15.00 price target on shares of Coya Therapeutics in a research report on Monday...
MarketBeat·15d ago
News Placeholder
D. Boral Capital Reaffirms Buy Rating for Coya Therapeutics (NASDAQ:COYA)
D. Boral Capital restated a "buy" rating and set a $15.00 price objective on shares of Coya Therapeutics in a research report on Tuesday...
MarketBeat·28d ago
News Placeholder
Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with...
Business Wire·28d ago
News Placeholder
Coya Therapeutics, Inc. (NASDAQ:COYA) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Shares of Coya Therapeutics, Inc. (NASDAQ:COYA - Get Free Report) have earned a consensus rating of "Moderate Buy" from the six brokerages that are presently covering the firm, MarketBeat reports...
MarketBeat·1mo ago
News Placeholder
Coya Therapeutics' (COYA) "Buy" Rating Reaffirmed at D. Boral Capital
D. Boral Capital reiterated a "buy" rating and set a $15.00 target price on shares of Coya Therapeutics in a research report on Tuesday...
MarketBeat·1mo ago
News Placeholder
Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS
Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with...
Business Wire·1mo ago
News Placeholder
Coya Therapeutics, Inc. (NASDAQ:COYA) Given Consensus Rating of "Moderate Buy" by Brokerages
Coya Therapeutics, Inc. (NASDAQ:COYA - Get Free Report) has been assigned an average rating of "Moderate Buy" from the six analysts that are presently covering the stock, MarketBeat reports. One...
MarketBeat·2mo ago
News Placeholder
Coya Therapeutics (NASDAQ:COYA) Receives "Buy" Rating from Chardan Capital
Chardan Capital restated a "buy" rating and issued a $14.00 target price on shares of Coya Therapeutics in a report on Friday...
MarketBeat·2mo ago
News Placeholder
Coya Therapeutics (NASDAQ:COYA) Rating Increased to Hold at Wall Street Zen
Wall Street Zen raised Coya Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...
MarketBeat·2mo ago
<
1
2
...
>

Latest COYA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.